The DMFS160: A new index for measuring post-radiation caries

Oral Oncology ◽  
2020 ◽  
Vol 108 ◽  
pp. 104823
Author(s):  
Erin Watson ◽  
Brady Eason ◽  
Matthew Kreher ◽  
Michael Glogauer
Author(s):  
NATÁLIA RANGEL PALMIER ◽  
ANA CAROLINA PRADO RIBEIRO ◽  
MARCIO AJUDARTE LOPES ◽  
THAIS BIANCA BRANDÃO ◽  
ALAN ROGER SANTOS-SILVA

2019 ◽  
Author(s):  
Stephanie Knollhoff ◽  
Jeff Searle

Abstract Introduction: Adherence to a swallowing exercise protocol and a common compliance barrier, oral pain, was evaluated and described. Methods: A four-week dysphagia exercise program was completed by 12 individuals with a history of base of tongue cancer who were experiencing latent dysphagia. Adherence to a dysphagia exercise program was quantified. Focused outcome measures on oral pain related to dysphagia exercises and exercise related sense of effort were also included. Results: Moderate to strong adherence was reported by 75% of participants. Overall, 78.9% of exercise sessions were completed. Individuals reported little to no pain associated with dysphagia exercises throughout protocol participation. Conclusions: Routine reminders and establishment of a tracking method supported adherence with a dysphagia exercise protocol. Oral pain and sense of effort associated with completing oral and dysphagia exercises were not demonstrated to be barriers to participation in a dysphagia exercise program in people who are several years post radiation therapy completion. Keywords: dysphagia, oropharyngeal cancer, latent dysphagia, swallowing exercises


Author(s):  
Débora Michelle Gonçalves de Amorim ◽  
Aretha Heitor Veríssimo ◽  
Anne Kaline Claudino Ribeiro ◽  
Rodrigo Othávio de Assunção e Souza ◽  
Isauremi Vieira de Assunção ◽  
...  

AbstractTo investigate the impact of radiotherapy on surface properties of restorative dental materials. A conventional resin composite—CRC (Aura Enamel), a bulk-fill resin composite—BFRC (Aura Bulk-fill), a conventional glass ionomer cement—CGIC (Riva self cure), and a resin-modified glass ionomer cement—RMGIC (Riva light cure) were tested. Forty disc-shaped samples from each material (8 mm diameter × 2 mm thickness) (n = 10) were produced according to manufacturer directions and then stored in water distilled for 24 h. Surface wettability (water contact angle), Vickers microhardness, and micromorphology through scanning electron microscopy (SEM) before and after exposition to ionizing radiation (60 Gy) were obtained. The data were statistically evaluated using the two-way ANOVA and Tukey posthoc test (p < 0.05). Baseline and post-radiation values of contact angles were statistically similar for CRC, BFRC, and RMGIC, whilst post-radiation values of contact angles were statistically lower than baseline ones for CGIC. Exposition to ionizing radiation statistically increased the microhardness of CRC, and statistically decreased the microhardness of CGIC. The surface micromorphology of all materials was changed post-radiation. Exposure to ionizing radiation negatively affected the conventional glass ionomer tested, while did not alter or improved surface properties testing of the resin composites and the resin-modified glass ionomer cement tested.


2021 ◽  
pp. 019459982110104
Author(s):  
Carly E. A. Barbon ◽  
Douglas B. Chepeha ◽  
Andrew J. Hope ◽  
Melanie Peladeau-Pigeon ◽  
Ashley A. Waito ◽  
...  

The current standard for the treatment of oropharynx cancers is radiation therapy. However, patients are frequently left with dysphagia characterized by penetration-aspiration (impaired safety) and residue (impaired efficiency). Although thickened liquids are commonly used to manage dysphagia, we lack evidence to guide the modification of liquids for clinical benefit in the head and neck cancer population. The objective of this study was to assess the impact of slightly and mildly thick liquids on penetration-aspiration and residue in 12 patients with oropharyngeal cancer who displayed penetration-aspiration on thin liquid within 3 to 6 months after completion of radiotherapy. Significantly fewer instances of penetration-aspiration were seen with slightly and mildly thick liquids as compared with thin ( P < .05). No differences were found across stimuli in the frequency of residue. Patients with oropharyngeal cancers who present with post–radiation therapy dysphagia involving penetration-aspiration on thin liquids may benefit from slightly and mildly thick liquids without risk of worse residue.


2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii45-ii45
Author(s):  
Sharon Gardner ◽  
Carl Koschmann ◽  
Rohinton S Tarapore ◽  
Jeffrey Allen ◽  
Wafik Zaky ◽  
...  

Abstract ONC201, an anti-cancer DRD2 antagonist and ClpP agonist, is in Phase II trials for adult H3 K27M-mutant diffuse midline gliomas. In adults, the recommended phase 2 dose (RP2D) of 625mg ONC201 once a week has been established as a biologically active dose that is well tolerated. Radiographic regressions with single agent ONC201 have been reported in adult recurrent H3 K27M-mutant glioma patients. This multi-arm, dose-escalation and dose-expansion trial determined the pediatric RP2D of ONC201 administered as an oral capsule (Arm A) or liquid formulation (Arm E) in post-radiation H3 K27M-mutant glioma (Arm A) or in newly diagnosed DIPG (Arm B) patients. Molecular assessments include intratumoral ONC201 concentrations (Arm C) and CSF H3 K27M DNA levels (Arm D). Enrollment as of April 30, 2020 is complete in Arm A (22) and Arm E (26) and continues in Arm B (18/24), Arm C (5/12), and Arm D (22/24). The RP2D of weekly 625mg ONC201 scaled by body weight was confirmed when administered as a capsule or a liquid formulation as a single agent or in combination with radiation without dose-limiting toxicity. The most frequent adverse events regardless of attribution to the drug were predominantly low grade: ONC201 capsule alone was headache (54.5%), nausea (36.4%), and fatigue (36.4%); ONC201 liquid formulation was vomiting (31.8%), headache (22.7%), VIth nerve disorder (22.7%); ONC201 capsules in combination with radiation (Arm B) was headache (47.1%), vomiting (52.9%), nausea (41.2%). Pharmacokinetic analysis in plasma of Arm A patients revealed T1/2: 8.4h; Tmax: 2.1h; Cmax: 2.3ug/mL; AUC0-tlast: 16.4ug/mL, with similar exposure across body weights. In conclusion, when scaled by body weight the ONC201 capsule or liquid formulation alone or in combination with radiation were associated with safety and pharmacokinetic profiles in pediatric H3 K27M-mutant diffuse midline glioma patients that are similar to the experience in adults.


2016 ◽  
Vol 04 (07) ◽  
pp. E794-E794
Author(s):  
Georgios Mavrogenis ◽  
Tom Moreels ◽  
Jean-Baptiste Chevaux ◽  
Maximilien Thoma ◽  
Pierre Deprez ◽  
...  

Author(s):  
C.D. Strange ◽  
G.S. Shroff ◽  
M.T. Truong ◽  
Q.-N. Nguyen ◽  
I. Vlahos ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document